Actively Recruiting
Study of Iodine125 Seed Implantation with Gemcitabine and Nab-Paclitaxel Chemotherapy versus Chemotherapy Alone for Metastatic Pancreatic Cancer
Led by Changhai Hospital · Updated on 2023-08-04
206
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical effectiveness and safety of combining endoscopic ultrasound EUS-guided radioactive iodine 125 seed implantation with Gemcitabine and nab-paclitaxel chemotherapy for treating metastatic pancreatic cancer. The study aims to determine if this minimally invasive local radiation combined with chemotherapy can improve overall survival compared to chemotherapy alone. It also monitors the side effects of this combination therapy. Participants in one group will receive the implantation of radioactive iodine 125 seeds guided by EUS, followed 48 hours later by chemotherapy cycles of Gemcitabine 1000 mgm2 and nab-paclitaxel 125 mgm2 on days 1 and 8 every 21 days. The control group will receive only the chemotherapy regimen without seed implantation. The treatment period and dosing schedule are consistent for both groups. During the study, participants will undergo assessments including overall survival tracked for up to 48 months as the primary outcome. Secondary measurements include adverse event rates, progression-free survival, tumor response, CA19-9 biomarker changes, metabolic response after two chemotherapy cycles, and pain evaluation using a visual analog scale. Safety and treatment effects will be carefully monitored throughout the study duration, which may last up to four years.
CONDITIONS
Brief Title
Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma
Research Team
J
Jia Yi Ma, M.D
K
Kai Xuan Wang, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here